ArticleViruses2019
Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant
Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 150 citations in OpenAlex.
- Safety of bacteriophage therapy in severe Staphylococcus aureus infection.Nature microbiology · 2020Trial
- Engineering the probioticSynthetic and systems biotechnology · 2026Article
- Bacteriophage therapy and antimicrobial resistance: a scoping review using the "One Health" framework.Infection · 2026Review
- Article
- Beyond Antibiotics: Therapeutic Strategies Utilizing Probiotics and Bacteriophages Against Drug-ResistantMicroorganisms · 2026Review
- Prophage landscapes in clinical MRSA: safety profiling and discovery of Lys81, a broad-spectrum bacteriolytic enzyme.Frontiers in microbiology · 2026Article
- Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy.Frontiers in immunology · 2026Review
- Large-scale analysis of bacterial genomes reveals thousands of lytic phages.Nature microbiology · 2026Article
- Optimizing phage-antibiotic combinations: impact of administration order against daptomycin non-susceptible (DNS) MRSA clinical isolates.Antimicrobial agents and chemotherapy · 2025Article
- CRISPR-Cas9 enables efficient genome engineering of the strictly lytic, broad-host-range staphylococcal bacteriophage K.Applied and environmental microbiology · 2025Article
- Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.MedComm · 2025Review
- Beyond antibiotics: exploring multifaceted approaches to combat bacterial resistance in the modern era: a comprehensive review.Frontiers in cellular and infection microbiology · 2025Review
- Ethical bioprospecting and microbial assessments for sustainable solutions to the AMR crisis.IUBMB life · 2025Review
- The Transcriptional Program ofViruses · 2024Article
- Phage therapy could be key to conquering persistent bacterial lung infections in children.npj antimicrobials and resistance · 2024Review
- Review
- Antibiotic resistance and tolerance: What can drug delivery do against this global threat?Drug delivery and translational research · 2024Article
- Alternative therapeutic strategies to treat antibiotic-resistant pathogens.Nature reviews. Microbiology · 2024Review
- Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in anAntimicrobial agents and chemotherapy · 2024Article
- Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers.Scientific reports · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages, viruses that only kill specific bacteria, are receiving substantial attention as nontraditional antibacterial agents that may help alleviate the growing antibiotic resistance problem in medicine. We describe the design and preclinical development of AB-SA01, a fixed-composition bacteriophage product intended to treat
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.